BTEC:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (USD)

ETF | Others |

Last Closing

USD 6.43

Change

-0.01 (-0.16)%

Market Cap

USD 0.48B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-1.09 (-0.40%)

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

-0.43 (-0.63%)

USD 292,109.19B
0R1O:LSE Amazon.com Inc.

+5.00 (+2.74%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-10.32 (-7.44%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.05 (-0.33%)

USD 553.83B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.12 (-0.72%)

USD 553.83B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

-7.00 (-0.35%)

USD 331.07B
0QZK:LSE Coca-Cola Co.

+0.55 (+0.88%)

USD 266.08B
0QZO:LSE 0QZO

+0.60 (+0.59%)

USD 258.54B

ETFs Containing BTEC:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.78% 33% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.78% 31% F 37% F
Trailing 12 Months  
Capital Gain 4.94% 33% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.94% 31% F 43% F
Trailing 5 Years  
Capital Gain 38.67% 55% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.67% 52% F 62% D
Average Annual (5 Year Horizon)  
Capital Gain 6.66% 60% D- 64% D
Dividend Return 6.66% 59% D- 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.71% 36% F 50% F
Risk Adjusted Return 33.80% 55% F 67% D+
Market Capitalization 0.48B 69% C- 59% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.